Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis

Chanasumon, Nongsak; Sriphojanart, Tueboon; Suchonwanit, Poonkiat

doi:10.2147/dddt.s156467

Cited by 40 publications

(44 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in clinical trials, it was noted to have a remarkable effect to increase the growth of eyelashes. It was repurposed for this indication and has been approved by the FDA and currently marketed for regrowth of eyelashes [18]. It appears to be effective across a variety of conditions, including chemotherapy, alopecia universalis, and normal individuals desiring thicker eyelashes [19].…”

Section: Bimatoprostmentioning

confidence: 99%

Pharmacological Treatment of Alopecia

Gensure¹

2018

Alopecia

View full text Add to dashboard Cite

In this chapter, we will explore non-surgical treatments of alopecia. Unlike many other areas of medicine, pharmacological treatments for alopecia are relatively new. There are only two treatments which are approved by the Food and Drug Administration (FDA); the rest are drugs developed for other indications which have gained popular off-label use to promote hair growth. The reasons for this are many, including the designation of alopecia by the FDA as a cosmetic disease. This designation has restricted alopecia development programs to compounds with virtually no side effects. Unfortunately, it has also led to off-label use of far more dangerous compounds as alopecia treatments, without the benefit of controlled trials. There is a growing recognition that alopecia, particularly alopecia areata and chemotherapy-induced alopecia, are disorders which significantly alter the quality of life, similar to acne vulgaris and psoriasis, and merit treatment accordingly. There have also been several recent advances in our understanding of the hair cycle, revealing new targets for developing alopecia therapies. As a result, there is a more robust slate of programs for developing new pharmacological treatments for alopecia. In this chapter, we will review current pharmacological treatments for alopecia and selected treatments under development (i.e., those with significant preclinical or clinical data which have appeared in the published literature).

show abstract

Section: Bimatoprostmentioning

confidence: 99%

Pharmacological Treatment of Alopecia

Gensure¹

2018

Alopecia

View full text Add to dashboard Cite

show abstract

“…Eyebrows grow as individual strands, not in multiple‐hair follicular units that are characteristic of scalp hair. The average length of eyebrows varies from 5 to 5.5 cm, with the width of 1.3–1.5 cm . Similarly to other hair, the eyebrow hair cycle consists of three phases: anagen, catagen and telogen .…”

Section: Introductionmentioning

confidence: 99%

“…The catagen phase lasts two to 3 weeks, while the telogen phase continues for two to 3 months. The anagen phase comprises approximately 10%, while the telogen phase 90% of eyebrow hair follicles …”

Section: Introductionmentioning

confidence: 99%

“…1 Similarly to other hair, the eyebrow hair cycle consists of three phases: anagen, catagen and telogen. 1 However, contrary to scalp hair, eyebrow anagen phase lasts only two to 4 weeks, which results in the growth of short hair. The catagen phase lasts two to 3 weeks, while the telogen phase continues for two to 3 months.…”

Section: Introductionmentioning

confidence: 99%

“…The anagen phase comprises approximately 10%, while the telogen phase 90% of eyebrow hair follicles. 1 The term madarosis origins from the ancient Greek word 'madao' meaning 'to fall off' and is defined as eyebrow or eyelash loss. 2 It could be a symptom of various dermatological and non-dermatological conditions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The value of dermoscopy in diagnosing eyebrow loss in patients with alopecia areata and frontal fibrosing alopecia

Waśkiel‐Burnat

Rakowska

Kurzeja

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction Alopecia areata and frontal fibrosing alopecia are common causes of eyebrow loss (madarosis). Objective Assessment of trichoscopic markers of eyebrow loss in alopecia areata and frontal fibrosing alopecia. Materials and methods The analysis included 50 patients with scalp alopecia areata with madarosis, 50 patients with scalp frontal fibrosing alopecia with madarosis and 50 healthy controls. In every case, trichoscopy of the eyebrow area was performed. Results Empty follicular and eccrine duct openings were observed in all patients and presented predominantly as yellow dots. Exclamation mark hairs were only detected in patients with alopecia areata (30%). Tapered hairs, broken hair, black dots and Pohl–Pinkus constrictions were observed in 14%, 36%, 26% and 4% of patients with alopecia areata, respectively, 4%, 16%, 2% and 0% of patients with frontal fibrosing alopecia, respectively, and they were not present in healthy controls. Dystrophic hairs and whitish areas were observed only in patients with frontal fibrosing alopecia (28% and 32%, respectively). Eyebrow regrowth in distinct directions was present in 32% of patients with frontal fibrosing alopecia, 8% of patients with alopecia areata and 4% of healthy controls. Diffuse erythema was detected in 60% of patients with alopecia areata and frontal fibrosing alopecia and 56% of healthy controls. Vellus hairs and upright regrowing hairs were observed in patients with alopecia areata (62% and 58%, respectively), frontal fibrosing alopecia (60% and 84%, respectively) and healthy controls (100% and 100%, respectively). Conclusion Trichoscopy of the eyebrow area is useful in diagnosing patients with isolated eyebrow loss. The most characteristic trichoscopic features of eyebrow loss in alopecia areata include exclamation mark hairs, tapered hairs, broken hairs and black dots. Frontal fibrosing alopecia of the eyebrows is characterized by the presence of dystrophic hairs, white areas and eyebrow regrowth in distinct directions.

show abstract

Principles of Topical Therapy

Buckley

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

As well as quantifying the burden of skin disease, epidemiology provides a direct method for assessing the causes of skin diseases. Identification of causes is a necessary step in pursuing the ultimate goal of disease prevention. This chapter covers the importance of thinking in terms of population rather than individuals, and provides a summary of the substantial global morbidity caused by skin disease. Risk factors from genetics to environment are outlined, along with describing the natural history and associations of common skin diseases. Finally, there is a description of how the principles and data from epidemiological studies provide the cornerstone to planning appropriate dermatology services. The chapter closes by providing the reader with a glossary of terms and a checklist to help with reading epidemiological studies.

show abstract

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis

Cited by 40 publications

References 58 publications

Pharmacological Treatment of Alopecia

Pharmacological Treatment of Alopecia

The value of dermoscopy in diagnosing eyebrow loss in patients with alopecia areata and frontal fibrosing alopecia

Principles of Topical Therapy

Contact Info

Product

Resources

About